- Home
- TGB vs SNDX Comparison
TGB vs SNDX Comparison
Compare TGB & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- SNDX
- Stock Information
- Founded
- TGB 1966
- SNDX 2005
- Country
- TGB Canada
- SNDX United States
- Employees
- TGB N/A
- SNDX N/A
- Industry
- TGB Precious Metals
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- SNDX Health Care
- Exchange
- TGB Nasdaq
- SNDX Nasdaq
- Market Cap
- TGB 972.9M
- SNDX 1.1B
- IPO Year
- TGB N/A
- SNDX 2016
- Fundamental
- Price
- TGB $3.16
- SNDX $16.24
- Analyst Decision
- TGB Hold
- SNDX Strong Buy
- Analyst Count
- TGB 1
- SNDX 10
- Target Price
- TGB $5.00
- SNDX $37.50
- AVG Volume (30 Days)
- TGB 4.4M
- SNDX 2.9M
- Earning Date
- TGB 08-06-2025
- SNDX 08-04-2025
- Dividend Yield
- TGB N/A
- SNDX N/A
- EPS Growth
- TGB N/A
- SNDX N/A
- EPS
- TGB N/A
- SNDX N/A
- Revenue
- TGB $424,271,553.00
- SNDX $77,933,000.00
- Revenue This Year
- TGB $18.29
- SNDX $434.67
- Revenue Next Year
- TGB $38.25
- SNDX $108.62
- P/E Ratio
- TGB N/A
- SNDX N/A
- Revenue Growth
- TGB N/A
- SNDX 2126.66
- 52 Week Low
- TGB $1.67
- SNDX $8.58
- 52 Week High
- TGB $3.68
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- TGB 48.75
- SNDX 79.83
- Support Level
- TGB $3.01
- SNDX $15.36
- Resistance Level
- TGB $3.51
- SNDX $16.33
- Average True Range (ATR)
- TGB 0.15
- SNDX 0.78
- MACD
- TGB -0.01
- SNDX 0.31
- Stochastic Oscillator
- TGB 30.39
- SNDX 96.87
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.